174 related articles for article (PubMed ID: 32650715)
1. Quantitative characterization of tumor cell-free DNA shortening.
Guo J; Ma K; Bao H; Ma X; Xu Y; Wu X; Shao YW; Jiang M; Huang J
BMC Genomics; 2020 Jul; 21(1):473. PubMed ID: 32650715
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
3. Refined characterization of circulating tumor DNA through biological feature integration.
Markus H; Chandrananda D; Moore E; Mouliere F; Morris J; Brenton JD; Smith CG; Rosenfeld N
Sci Rep; 2022 Feb; 12(1):1928. PubMed ID: 35121756
[TBL] [Abstract][Full Text] [Related]
4. A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
Cario CL; Chen E; Leong L; Emami NC; Lopez K; Tenggara I; Simko JP; Friedlander TW; Li PS; Paris PL; Carroll PR; Witte JS
BMC Cancer; 2020 Aug; 20(1):820. PubMed ID: 32859160
[TBL] [Abstract][Full Text] [Related]
5. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
6. Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics.
Sanchez C; Roch B; Mazard T; Blache P; Dache ZAA; Pastor B; Pisareva E; Tanos R; Thierry AR
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33571170
[TBL] [Abstract][Full Text] [Related]
7. Fragmentation patterns of cell-free DNA and somatic mutations in the urine of metastatic breast cancer patients.
Lin S; Wang S; Xu B
J Cancer Res Ther; 2024 Apr; 20(2):563-569. PubMed ID: 38454812
[TBL] [Abstract][Full Text] [Related]
8. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
9. Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples.
Huang Y; Mu J; Qi L; Ge W; Fang X; Song Y; Yuan Y; Zheng S
Clin Chem Lab Med; 2020 Aug; 58(9):1451-1459. PubMed ID: 32229658
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
11. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
12. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.
Snyder MW; Kircher M; Hill AJ; Daza RM; Shendure J
Cell; 2016 Jan; 164(1-2):57-68. PubMed ID: 26771485
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling.
Cheng THT; Jiang P; Teoh JYC; Heung MMS; Tam JCW; Sun X; Lee WS; Ni M; Chan RCK; Ng CF; Chan KCA; Chiu RWK; Lo YMD
Clin Chem; 2019 Jul; 65(7):927-936. PubMed ID: 30988170
[TBL] [Abstract][Full Text] [Related]
14. Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.
Yeh YM; Lin PC; Lee CT; Chen SH; Lin BW; Lin SC; Chen PC; Chan RH; Shen MR
Mol Cancer; 2020 Oct; 19(1):150. PubMed ID: 33106181
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
16. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
Schweizer MT; Gulati R; Beightol M; Konnick EQ; Cheng HH; Klemfuss N; De Sarkar N; Yu EY; Montgomery RB; Nelson PS; Pritchard CC
Prostate; 2019 May; 79(7):701-708. PubMed ID: 30865311
[TBL] [Abstract][Full Text] [Related]
17. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
[TBL] [Abstract][Full Text] [Related]
18. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
19. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation.
Ivanov M; Baranova A; Butler T; Spellman P; Mileyko V
BMC Genomics; 2015; 16 Suppl 13(Suppl 13):S1. PubMed ID: 26693644
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]